Insulin therapy in 2011;Inzulinová léčba v roce 2011

Vnitrni Lekarstvi

Volumn 57, Issue 11, 2011, Pages 930-936

  Perušičová, Jindřiška ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Early insulin therapy; Insulin analogues; The aims of insulin therapy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ARTICLE; ARTIFICIAL INTELLIGENCE; B LYMPHOCYTE; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; LYMPHOCYTE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; SIDE EFFECT; STEM CELL; WEIGHT GAIN; DIABETES MELLITUS; REVIEW;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 83055163304     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Abe S, Inoue G, Yamada S et al. Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring. Diabetes Metab Syndr Obes 2011; 4: 283-288.
2. Barag SH. Insulin Therapy for Management of Type 2 Diabetes Mellitus: Strategies for Initiation and Long-term Patient Adherence. J Am Osteopath Assoc 2011; 111 (7 Suppl 5): S13-S19.
3. Benroubi M. Fear, guilt feelings and misconceptions: Barriers to effective insulin treatment in type 2 diabetes. Diabetes Res Clin Pract 2011; 93 (Suppl 1): S97-S99.
4. Blevins T. Control of postprandial glucose levels with insulin in type 2 diabetes. Postgrad Med 2011; 123: 135-147.
5. Boldo A, Comi RJ. Clinical Experience with U-500 Insulin: Risks and Benefits. Endocr Pract 2011; 29: 1-17.
6. Cengiz E, Sherr JL, Weinzimer SA et al. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Rev Med Devices 2011; 8: 449-458.
7. Curran K, Nichols E, Xie E et al. An intensive insulinotherapy mobile phone application built on artificial intelligence techniques. J Diabetes Sci Technol 2010; 4: 209-220.
8. Danne T, Kordonouri O, Holder M et al. Prevention of Hypoglycemia by Using Low Glucose Suspend Function in Sensor-Augmented Pump Therapy. Diabetes Technol Ther 2011; Aug 9. [Epub ahead of print].
9. Das AK, Shah S. History of diabetes: from ants to analogs. J Assoc Physicians India 2011; 59 (Suppl): 6-7.
10. Gerber PA, Spirk D, Brändle M et al. Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. Swiss Med WkIy 2011; 141: w13218.
11. Godfrey KJ, Mathew B, Bulman JC et al. Stem cell-based treatments for Type 1 diabetes mellitus: bone marrow, embryonic, hepatic, pancreatic and induced pluripotent stem cells. Diabet Med 2011; Aug 29. [Epub ahead of print].
12. Heise T, Tack CJ, Cuddihy R et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011; 34: 669-674.
13. Hermanns N, Kulzer B, Maier B et al. The effect of an education programme (MEDIAS 2 ICT) involving intensive insulin treatment for people with type 2 diabetes. Patient Educ Couns 2011; Jun 27. [Epub ahead of print].
14. Hisasue J, Fukuyama S, Nakagaki N et al. Inhalative administration of insulin using a new bubble jet atomization device. Fukuoka Igaku Zasshi 2011; 102: 215-222.
15. Holt P. Taking hypoglycaemia seriously: diabetes, dementia and heart disease. Br J Community Nurs 2011; 16: 246-249.
16. Hu Y, Li L, Xu Y et al. Short-Term Intensive Therapy in Newly Diagnosed Type 2 Diabetes Partially Restores Both Insulin Sensitivity and β-Cell Function in Subjects With Long-Term Remission. Diabetes Care 2011; 34: 1848-1853.
17. Lavernia F. What options are available when considering starting insulin: premix or basal? Diabetes Technol Ther 2011; 13 (Suppl 1): S85-S92.
18. Levin PA, Mersey JH, Zhou S et al. Clinical Outcomes Using Long-Term Combination Therapy With Insulin Glargine and Exenatide In Patients With Type 2 Diabetes. Endocr Pract 2011; 8: 1-28.
19. Lin CH, Huang CH, Tsai JS et al. Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan. Endocr J 2011; Aug 9. [Epub ahead of print].
20. Mooradian AD. Special considerations with insulin therapy in older adults with diabetes mellitus. Drugs Aging 2011; 28: 429-438.
21. Niswender KD. Basal insulin: physiology, pharmacology, and clinical implications. Postgrad Med 2011; 123: 17-26.
22. Niu M, Lu Y, Hovgaard L et al. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine 2011; 6: 1155-1166.
23. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011; 13 (Suppl 1): S5-S14.
24. Pennartz C, Schenker N, Menge BA et al. Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes. Diabetes Care 2011; 34: 2048-2053.
25. Ranjit Unnikrishnan I, Anjana RM, Mohan V. Importance of controlling diabetes early - the concept of metabolic memory, legacy effect and the case for early insulinisation. J Assoc Physicians India 2011; 59 (Suppl): 8-12.
26. Renard E, Dubois-Laforgue D, Guerci B on Behalf Of The Variability Study Group. Non-Inferiority of Insulin Glargine Versus Insulin Detemir on Blood Glucose Variability in Type 1 Diabetes Patients: A Multicenter, Randomized, Crossover Study. Diabetes Technol Ther 2011; Aug 2 [Epub ahead of print].
27. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther 2011; 13 (Suppl 1): S103-S108.
28. Starkman H, Frydman E, Bustami R. Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control. J Pediatr Endocrinol Metab 2011; 24: 369-371.
29. Swinnen SG, Simon AC, Holleman F et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; 7: CD006383.
30. Zarogoulidis P, Papanas N, Kouliatsis G et al. Inhaled Insulin: Too Soon To Be Forgotten? J Aerosol Med PuIm Drug Deliv 2011; 24: 213-223.
31. Zeng L, Lu H, Deng H et al. Noninferiority Effects on Glycemic Control and β-Cell Function Improvement in Newly Diagnosed Type 2 Diabetes Patients: Basal Insulin Monotherapy Versus Continuous Subcutaneous Insulin Infusion Treatment. Diabetes Technol Ther 2011; Aug 30 [Epub ahead of print].
32. Zhu FF, Zhang PB, Zhang DH et al. Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells. Diabetologia 2011; 54: 2325-2336.
33. Ziesmer AE, Kelly KC, Guerra PA et al. U-500 Regular Insulin Use In Insulin Resistant Type 2 Diabetic Veteran Patients. Endocr Pract 2011; 8: 1-15.